Abstract
It is still uncertain whether total bilirubin per se is a risk factor for osteoporosis in postmenopausal women and no study has so far examined this important issue. This study was designed to assess the sheer effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. In the present study, postmenopausal female subjects without potential liver disease (n = 918) who underwent measurement of bone mineral density were enrolled. Correlation and logistic regression analysis were used to assess the relationship between total bilirubin and other variables. As a result, subjects with osteoporosis had a significantly lower total bilirubin level (P = 0.005). A 0.1 mg/dl increase in total bilirubin was associated with reduced odds ratio of the risk by 38 % for osteoporosis [OR 0.62 (95 % CI 0.52–0.88), P = 0.012] after adjustment for several variables. Total bilirubin was independently associated with BMD [coefficient = 0.41, 95 % CI (0.35–0.47), P < 0.001 for lumbar spine and coefficient = 0.44, 95 % CI (0.36–0.48), P < 0.001 for femur neck]. A positive correlation could be observed with significant difference between total bilirubin and z-score (r = 0.33, P < 0.001 for lumbar spine and r = 0.37, P < 0.001 for femur neck) and total bilirubin was positively correlated with serum calcium (r = 0.13, P < 0.001) as well. Therefore, this study demonstrates an independent inverse association between total bilirubin and the prevalence of osteoporosis in postmenopausal women without potential liver disease. Total bilirubin would be useful as a provisional new risk factor of osteoporosis in such a population.
Similar content being viewed by others
References
Hay JE (1995) Bone disease in cholestatic liver disease. Gastroenterology 108:276–283
Leslie WD, Bernstein CD, Leboff MS (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125:941–966
Conn HO (1981) A peek at the Child-Turcotte classification. Hepatology 1:673–676
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871
Pares A, Rodes J (2003) Natural history of primary biliary cirrhosis. Clin Liver Dis 7:779–794
Roll J, Boyer JL, Barry D, GB Klatskin (1983) The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 308:1–7
Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE (1999) Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29:39–43
Menon KVN, Angulo P, Weston S, Dickson ER, Lindor KD (2001) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35:316–323
Ormarsdóttir S, Ljunggren O, Mallmin H, Michaëlsson K, Lööf L (2002) Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 14:43–48
Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER (1995) Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 21:389–392
Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, Dubreuil M, Peris P, Enjuanes A, Martinez de Osaba MJ, Alvarez L, Monegal A, Combalia A, Parés A (2011) Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 54:2104–2113
World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report no. 843. World Health Organization, Geneva
Kanis JA, Melton LJ 3rd, Christiansen C, Johnson CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141
van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F (1998) Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97:2302–2306
Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, Jones D (2001) Osteoporosis in primary biliary cirrhosis revisited. Gut 49:282–287
Kuyumcu ME, Yesil Y, Oztürk ZA, Cınar E, Kızılarslanoglu C, Halil M, Ulger Z, Yesil NK, Cankurtaran M, Arıoğul S (2012) The association between homocysteine (hcy) and serum natural antioxidants in elderly bone mineral densitometry (BMD). Arch Gerontol Geriatr 55:739–743
Halliwell B (1994) Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344:721–724
Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88:1523–1527
Zhang YB, Zhong ZM, Hou G, Jiang H, Chen JT (2011) Involvement of oxidative stress in age-related bone loss. J Surg Res 169:e37–e42
Sánchez-Rodríguez MA, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-Núñez VM (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8:124
Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J (2002) Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine betasynthase-deficient mice. Arterioscler Thromb Vasc Biol 22:34–41
Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 314:197–207
Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ (2003) A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112:915–923
Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146:728–735
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046
Stocker R, Glazer AN, Ames BN (1987) Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 84:5918–5922
Stocker R, Peterhans E (1989) Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun 6:57–66
Wu TW, Fung KP, Wu J, Yang CC, Weisel RD (1996) Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51:859–862
Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D (1998) Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 352:165–174
Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99:16093–16098
Lin JP, Vitek L, Schwertner HA (2010) Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 56:1535–1543
Kirkby KA, Adin CA (2006) Products of heme oxygenase and their potential therapeutic applications. Am J Physiol Renal Physiol 290:F563–F571
Sabio JM, Vargas-Hitos JA, Mediavilla JD, Navarrete-Navarrete N, Zamora-Posadas M, Pérez-Vicente S, Hidalgo-Tenorio C, Díaz-Chamorro A, Jáimez L, Jiménez-Alonso J, Grupo Lupus Virgen de las Nieves (2010) Correlation of asymptomatic hyperuricaemia and serum uric acid levels with arterial stiffness in women with systemic lupus erythematosus without clinically evident atherosclerotic cardiovascular disease. Lupus 19:591–598
Zhang Z, Bian L, Choi Y (2012) Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology 63:420–428
Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ, Sambrook PN (2013) Serum uric acid plays a protective role for bone loss in peri-and postmenopausal women: a longitudinal study. Bone 52:400–406
Acknowledgments
The authors thank all the numerous physicians and study nurses who participated in data collection.
Conflict of interest
All other authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
L.-Q. Bian, R.-Z. Li and Z.-Y. Zhang contributed equally to this work.
About this article
Cite this article
Bian, LQ., Li, RZ., Zhang, ZY. et al. Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Metab 31, 637–643 (2013). https://doi.org/10.1007/s00774-013-0452-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-013-0452-y